Market Cap (In EUR)
162.4 Million
Revenue (In EUR)
2.08 Million
Net Income (In EUR)
-15.38 Million
Avg. Volume
25.04 Thousand
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.89-13.3
- PE
- -
- EPS
- -
- Beta Value
- 0.453
- ISIN
- BE0974363955
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Stijn Van Rompay
- Employee Count
- -
- Website
- https://hyloris.com
- Ipo Date
- 2020-06-29
- Details
- Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
More Stocks
-
UNIQPT Ulima Nitra Tbk
UNIQ
-
SANWS&W Seed Company
SANW
-
CGSI
-
REFEXRefex Industries Limited
REFEX
-
IROHW
-
TGOPF3i Group plc
TGOPF
-
2668
-
334890